September 30th, 2010

Researchers at Children’s Hospital in Philadelphia, as well as other top pediatric hospitals, have developed a technique that improves the survival rate from neuroblastoma through a process known as immunotherapy.

This is the first major advancement in over a decade for high-risk neuroblastoma patients, and it has increased “two-year survival without relapse to 66 percent from 46 percent.”  Immunotherapy has become the standard of care for patients and has instilled optimism in both patients and their families.

Read more.